Treatment of atrophic and irritative vulvovaginal symptoms with an anhydrous lipogel and its complementary effect with vaginal estrogenic therapy: New evidences;Trattamento dei disturbi trofici e irritativi vulvovaginali con un lipogel anidro e suo effetto complementare alla terapia estrogenica per via vaginale: Nuovi approfondimenti

Minerva Ginecologica

Volumn 62, Issue 4, 2010, Pages 287-291

  Del Pup, L ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Atrophy menopause; Boswellic acid; Candidiasis vulvovaginal

Indexed keywords

ALPHA TOCOPHEROL; BOSWELLIC ACID; LIPOGEL; TERPENOID; UNCLASSIFIED DRUG;

ADULT; DRUG EFFICACY; ERYTHEMA; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PRESCRIPTION; REVIEW; SYMPTOMATOLOGY; VAGINA ATROPHY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VULVA DISEASE; VULVOVAGINAL DISEASE;

ADMINISTRATION, INTRAVAGINAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; ATROPHY; CANDIDIASIS, VULVOVAGINAL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROGEL; LIPIDS; OINTMENTS; PRURITUS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TRITERPENES; VITAMIN E; VULVOVAGINITIS;

EID: 78650732492     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Cardozo L, Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynaecol 1998; 92: 722-7. (Pubitemid 28440818)
2. Writing Group for the Women's Health Initiative Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health inititive randomized controlled trial. JAMA 2002; 288: 321-33.
3. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W et al. for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen-progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 58-66.
4. Million Women Study Collaborators. Breast cancer and hormone - replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
5. Del Pup L Controversie terapeutiche. In: Baldi S, Donati Sarti C. Menopausa e terza età: up-to-date. L'esperienza italiana. Critical Medicine Publishing Roma 2004; 659-688.
6. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergström R et al. Low-potency oestrogen and risk of endometrial cancer; a case-control study. Lancet 1999; 353: 1824-8.
7. Birkhauser M, Huber P, Mall Haefeli M. Absorption, tolerability and clinical effect of estriol vaginal suppo- sitories with sustained release of active substance. Arch of Gynecology 1986; 239: 228-31.
8. Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW et al. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006; 8: R11.
9. Foidart JM, Vervliet J, Buytaert P. Double blind placebo controlled evaluation of the efficacy of a susteined release vaginal formulation of estrio] in .alleviating urogenital and systemic menopausal complaints. Maturitas 1991; (13): 99-107.
10. Wesel S, Etienne J, Lestienne MC. Clinical, cytological and biological study of the intravaginal administration of oestriol (Ortho-Gynest) in post menopausal patients. Maturitas 1981; 3: 271-7. (Pubitemid 12145696)
11. Del Pup L. Estriólo e disturbi urogenitali. Atti SIGO 2002 CIC Roma 2002: 19-25.
12. Weissenbacher ER, Schulze K. Estriol for the alleviation of systemic and urogenital postmenopausal complaints. Int J Exp Clinical Chemotherapy 1991; 4: 19-25.
13. Poeckel D, Werz O. Boswellic acid: biological action and molecular targets. Curr Med Chem 2006; 13: 3359-69.
14. Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Medizinsche Wochenschrift 2002; 152: 373-8.
15. Sailer ER, Subramanian LR, Rail B, Hoernlein RF, Ammon HP, Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5lipoxygenase inhibitory activity. Br J Pharmacol 1996; 117: 615-8.
16. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-6.
17. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995; 47: 1212-6.
18. Sailer ER, Schweizer S, Boden SE, Ammon HP, Safayhi H. Characterization of an acetyl-íl-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5lipoxygenase using photoaffinity labeling. Eur J Biochem 1998; 256: 364-8.
19. Perosino E, Fasola E, Follador E, Bernabei G, Creti GP. Il ruolo anti-aging dell'acido boswelico in associazione alla vit. E nella terapia topica degli organi genitali esterni. Congresso SIES; Bologna 2009.
20. Di Venanzio M, Kanako TrentiL, Gravotta E., Perosino E. Impiego a breve termine di un nuovo lipogel a base di acido boswellico nei disturbi cutanei dell'area genitale in postmenopausa. J Clin Med 2010; 9: 1-7.
21. Del Pup L. Estriolo depot e gel protettivi nel trattamento dei disturbi urogenitali e vulvovaginali in menopausa: efficacia e sicurezza. Rivista di Ginecologia Consultoriale 2009; 21: 15-22.